Download PDF
Synlett 2004(6): 1039-1043  
DOI: 10.1055/s-2004-822887
LETTER
© Georg Thieme Verlag Stuttgart · New York

Synthesis of Medicinally Interesting 2,4-Diamino-9H-pyrimido[4,5-b]indol-6-ols via Extension of the Nenitzescu Reaction

Bernd Dotzauer, Reinhard Troschütz*
Department of Medicinal Chemistry, Emil-Fischer-Center, Friedrich-Alexander-University, Erlangen-Nürnberg, Schuhstraße 19, 91052 Erlangen, Germany
Fax: +49(9131)8522587; e-Mail: troschuetz@pharmazie.uni-erlangen.de;
Further Information

Publication History

Received 14 November 2003
Publication Date:
25 March 2004 (online)

    Permissions and Reprints All articles of this category

Abstract

The title compounds 6 were prepared by a one-step procedure from 1,4-benzoquinone (1) and pyrimidine-2,4,6-triamines 2 via an extension of the Nenitzescu reaction. Formation of 9H-­pyrimido[4,5-b]indoles 6 can be calculated by 13C NMR values of C-5 of the pyrimidine-2,4,6-triamines 2.

Key words

N-heterocycles - cyclizations - Nenitzescu reaction - 1,4-quinones - nucleophilic additions

    References

  • 1 Bundy GL. Ayer DE. Banitt LS. Belonga KL. Mizsak SA. Palmer JR. Tustin JM. Chin JE. Hall ED. Linseman KL. Richards IM. Scherch HM. Sun FF. Yonkers PA. Larson PG. Lin JM. Padbury GE. Aaron CS. Mayo JK. J. Med. Chem.  1995,  38:  4161 
    CrossrefGoogle Scholar
  • 2 Bundy G. Banitt LS. Doborowski PJ. Palmer JR. Schwartz TM. Zimmermann DC. Lipton MF. Mauragis MA. Veley MF. Appell RB. Clouse RC. Daugs ED. Org. Process Res. Dev.  2001,  5:  144 
    CrossrefGoogle Scholar
  • 3 Traxler PM. Furet P. Mett H. Buchdunger E. Meyer T. Lydon N. J. Med. Chem.  1996,  39:  2285 
    CrossrefPubMedGoogle Scholar
  • 4 Lowinger T, Shimazaki M, Sato H, Tanaka K, Tsuno N, Marx K, Yamamoto M, Urbahns K, Gantner F, Okigami H, Nakashima K, Takeshita K, Bacon K, Komura H, and Yoshida N. inventors; PCT Int. Appl. WO  03/037898. 
  • 5a Glushkov RG. Volskova VA. Magidson OYu. Khim. Farm. Zh.  1967,  1:  25 
    CrossrefGoogle Scholar
  • 5b Grob CA. Weinbach OJ. Helv. Chim. Acta  1961,  44:  1748 
    CrossrefGoogle Scholar
  • 6 Showalter HDH. Bridges AJ. Zhou H. Sercel AD. McMichael A. Davis WF. J. Med. Chem.  1999,  42:  5464 
    CrossrefGoogle Scholar
  • 7 Eger K. Lanzner W. Rothenhäusler K. Liebigs Ann. Chem.  1993,  465 
    Google Scholar
  • 8a Zhang YM. Razler T. Jackson PF. Tetrahedron Lett.  2002,  43:  8235 
    Google Scholar
  • 8b Lapachev VV. Stadlbauer W. Kappe T. Monatsh. Chem.  1988,  119:  97 
    Google Scholar
  • 8c Vlasova MI. Kogan NA. Khim. Geterotsikl. Soedin.  1982,  7:  935 
    Google Scholar
  • 8d Wright GE. J. Heterocycl. Chem.  1976,  13:  539 
    Google Scholar
  • 9a Pindur U. Pharm. Unserer Zeit  1987,  16:  47 
    CrossrefGoogle Scholar
  • 9b Anderson WK. Gopalsamy A. Peech SR. J. Med. Chem.  1994,  37:  1955 
    CrossrefGoogle Scholar
  • 9c Auclaire C. Paoletti C. J. Med. Chem.  1981,  24:  289 
    CrossrefGoogle Scholar
  • 10 Gribble GW. Synlett  1991,  289 
    Article in Thieme ConnectGoogle Scholar
  • 11 Gribble GW. Saulnier MG. Obaza-Nutaitis JA. Ketcha DM. J. Org. Chem.  1992,  57:  5891 
    CrossrefGoogle Scholar
  • 12 Allen GR. In Organic Reactions   Vol. 30:  Wiley; New York: 1973.  p.337 
    Google Scholar
  • 13a Troschütz R. Arch. Pharm. (Weinheim, Ger.)  1989,  322:  285 
    Google Scholar
  • 13b Troschütz R. Arch. Pharm. (Weinheim, Ger.)  1984,  317:  709 
    Google Scholar
  • 14 Bernier JL. Hénichart JP. Vaccher C. Houssin R. J. Org. Chem.  1980,  45:  1493 
    Google Scholar
  • 15 Bernier JL. Hénichart JP. J. Org. Chem.  1981,  46:  4197 
    Google Scholar
  • 16a Allen GR. Pidacks C. Weiss MJ. J. Am. Chem. Soc.  1966,  88:  2536 
    CrossrefGoogle Scholar
  • 16b Patrick JB. Saunders EK. Tetrahedron Lett.  1979,  20:  4009 
    CrossrefGoogle Scholar
  • 17 Troschütz R. Anders E. Arch. Pharm. (Weinheim, Ger.)  1992,  325:  341 
    Google Scholar
  • 18 Kuckländer U. Tetrahedron  1973,  29:  921 
    CrossrefGoogle Scholar
  • 19 Barret R. Daudon M. Tetrahedron Lett.  1990,  34:  4871 
    Google Scholar
  • 20 Malesani G. Marcolin F. Rodighiero G. J. Med. Chem.  1970,  13:  161 
    CrossrefGoogle Scholar
  • 21 Warren JD. Ving JL. Angier RA. J. Heterocycl. Chem.  1979,  16:  1617 
    CrossrefGoogle Scholar
  • The 6-aminopyrimidines 2 were prepared according to the following literature:
  • 22a Fletcher I. inventors; Ger. Offen, DE  2749902A1. 
    Google Scholar
  • 22b Roth B. Smith J. Hultquist M. J. Chem. Soc.  1949,  2490 
    Google Scholar
  • 22c Nishigaki S. Senga K. Yoneda F. Chem. Pharm. Bull.  1971,  19:  1526 
    Google Scholar
  • 22d Meyer H, Wehinger E, Garthoff B, and Kazda S. inventors; Ger. Offen, DE  3501696A1. 
    Google Scholar
23

Typical Procedure for the Preparation of 6a and 9d.
2,4-Diamino-9 H -pyrimido[4,5- b ]indol-5-ol ( 6a):
To a clear solution of 1.27 g (10 mmol) pyrimidine-2,4,6-triamine(2a) in 50 mL boiling glacial acetic acid 1.3 g (12 mmol) of 1,4-benzoquinone(1) was added, and the mixture refluxed for 6 h. The solvent was removed in vacuo and the dark residue purified by MPLC (silica gel) using CHCl3/MeOH 4:1 as eluent. Colorless powder, yield 695 mg (31.8%); mp >300 °C.
IR (NaCl): νmax = 3127, 1589, 1471, 1409, 1199 cm-1. UV (CH3OH): λmax (log ε) = 209 nm (4.205), 237 (3.255), 259 (4.330), 293 (2.005), 316 (1.409), 324 (1.307). 1H NMR (360 MHz, d 6-DMSO): δ = 5.82 (s, 2 H, NH2, with D2O exchangeable), 6.49 (s, 2 H, NH2, with D2O exchangeable), 6.63 (dd, 1 H, H-7, J 1 = 8.5 Hz, J 2 = 2.2 Hz), 7.01 (d, 1 H, H-8, J = 8.5 Hz), 7.35 (d, 1 H, H-5, J = 2.2 Hz), 8.66 (s, 1 H, OH, with D2O exchangeable), 10.76 (s, 1 H, NH, with D2O exchangeable). 13C NMR (90.6 MHz, d 6-DMSO): δ = 89.0 (C-4a), 105.7 (C-5), 110.0 (C-7), 110.3 (C-8), 122.3 (C-4b), 129.5 (C-8a), 151.2 (C-6), 159.0 (C-2), 158.3, 161.7 (C-4, C-9a). MS: m/z (%) = 215 (100) [M+], 198 (19.4), 173 (30.8). Found: C, 55.68; H, 413; N, 32.69. For C10H9N5O (215.22) calcd: C, 55.81; H, 4.22; N, 32.54.
7,9-Bis(dimethylamino)-11 H -pyrimido[5′,4′:4,5]pyr-rolo[2,3- f ]quinoxalin-5-ol ( 9d): A mixture of 181 mg (1 mmol) of N 2,N 2,N 4,N 4-tetramethylpyrimidine-2,4,6-triamine (2d) and 160 mg (1 mmol) of quinoxaline-5,8-dione (8d) were dissolved in 25 mL of absolute EtOH. After addition of 0.5 mL glacial acetic acid the mixture was refluxed for 6 h. The solvent was removed in vacuo and the residue purified by MPLC (silica gel) using CHCl3/MeOH 95:5 as eluent. Light green powder, yield 112 mg (34.6%); mp >300 °C.
IR (NaCl): νmax = 3747, 3226, 2927, 2852, 1662, 1556, 1182, 1070 cm-1. 1H NMR (360 MHz, d 6-DMSO): δ = 3.20 (s, 12 H, NMe2), 7.58 (s, 1 H, H-6), 8.75 (d, 1 H, J = 1.8 Hz), 8.87 (d, 1 H, J = 1.8 Hz), 9.63 (s, 1 H, OH, with D2O exchangeable), 12.2 (s, 1 H, NH, with D2O exchangeable). MS: m/z (%) = 323 (100) [M+], 308 (25.8), 294 (78.8), 161,7 (14.5). Found: C, 59.61; H, 5.23; N, 30.39. For C16H17N7O (323.36) calcd: C, 59.43; H, 5.30; N, 30.32.